Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden

Table 2

Characteristics of chemotherapy regimens incorporated into the model.

Regimen	Mean dose per cycle	Admissions/outpatient clinic attendances per cycle
CYVADIC^∧	600 mg/m^2 cyclophosphamide	4 outpatient clinic attendances
	1 mg/m^2 vincristine
	30 mg/m^2 doxorubicin
	250 mg/m^2 dacarbazine
Docetaxel	100 mg/m^2docetaxel	1 outpatient clinic attendance
Doxorubicin	75 mg/m^2 doxorubicin	1 outpatient clinic attendance
Doxorubicin/ifosfamide	66 mg/m^2 doxorubicin	3-4-day admission
	8.5 g/m^2 ifosfamide
Ifosfamide	12.5 g/m^2 ifosfamide	4-day admission or 2 outpatient clinic attendances
Ifosfamide/epirubicin	100 mg/m^2 epirubicin	3-day admission
	5 g/m^2 ifosfamide
Gemcitabine	1,000 mg/m^2 gemcitabine	2 outpatient clinic attendances
Gemcitabine/dacarbazine	1,766 mg/m^2 gemcitabine	2 outpatient clinic attendances
	700 mg/m^2dacarbazine
Gemcitabine/docetaxel	1,000 mg/m^2 gemcitabine	2 outpatient clinic attendances
	75 mg/m^2 docetaxel
Gemcitabine/paclitaxel	1,000 mg/m^2 gemcitabine	2 outpatient clinic attendances
	125 mg/m^2 paclitaxel
Gemcitabine/vinorelbine	1,250 mg/m^2 gemcitabine	2 outpatient clinic attendances
	25 mg/m^2 vinorelbine
Liposomal doxorubicin	50 mg/m^2doxorubicin	1 outpatient clinic attendance
Trabectedin	1.3 mg/m^2trabectedin	2-day admission
Trofosfamide	200 mg/m^2trofosfamide	Oral administration over ~10 days, no hospital attendance
Trofosfamide/etoposide	150 mg/m^2 trofosfamide	Oral administration over ~10 days, no hospital attendance
	25 mg/m^2 etoposide

 ^∧CYVADIC: cyclophosphamide, vincristine, adriamycin, and dacarbazine.